Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 3/20 | 0.43 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.39 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.39 |
| ▸ | TYMP | P19971 | 1/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL781934 | 0.91 | P2RY14 (0.38) | P2RY14SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL780531 | 0.91 | P2RY14 (0.38) | P2RY14SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL800758 | 0.90 | P2RY14 (0.38) | P2RY14SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL800304 | 0.90 | P2RY14 (0.38) | P2RY14SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL21461830 | 0.89 | P2RY14 (0.41) | P2RY14SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL21475704 | 0.86 | P2RY14 (0.40) | P2RY14SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL8390570 | 0.85 | SLC28A1 (0.54) | P2RY14SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL4387787 | 0.83 | TYMP (0.53) | P2RY14SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL13589363 | 0.83 | TYMP (0.53) | P2RY14SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL8970268 | 0.83 | P2RY14 (0.46) | P2RY14SLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927140-B2 | Compositions and methods for reverse automated nucleic acid synthesis | THE UNIVERSITY OF TOLEDO (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190315794-A1 | Compositions and Methods for Reverse Automated Nucleic Acid Synthesis | THE UNIVERSITY OF TOLEDO (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315794-A1 | Compositions and Methods for Reverse Automated Nucleic Acid Synthesis | RNGTT, POLRMT, POLN | P2RY14 3406/4885SLC28A1 1608/4885SLC28A2 1710/4885 |
| US-10927140-B2 | Compositions and methods for reverse automated nucleic acid synthesis | RNGTT, POLRMT, POLN | P2RY14 3406/4885SLC28A1 1608/4885SLC28A2 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.